NightstaRx Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:NightstaRx Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11338
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NightstaRx Ltd (NightstaRx) a subsidiary of Nightstar Therapeutics PLC is a clinical-stage gene therapy company that engaged in developing and commercializing novel. The company also involved in providing one-time treatments for patients suffering from rare inherited retinal diseases. It provides NSR-REP1, is developed for the treatment of choroideremia (CHM), degenerative, X-linked genetic retinal disorder. NightstaRx is headquartered in London, England, the UK.

NightstaRx Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NightstaRx Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
NightstaRx Ltd, Medical Devices Deals, 2012 to YTD 2018 9
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
NightstaRx Raises USD45 Million in Series C Financing 11
NightstaRx Raises USD35 Million in Series B Financing Round 12
Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13
NightstaRx Raises US$19.8 Million In Venture Financing 14
Licensing Agreements 15
NightstaRx Enters into Licensing Agreement with Oxford University 15
NightstaRx Expands Licensing Agreement with Isis Innovation 16
NightstaRx Enters into Licensing Agreement with Oxford University Innovation 17
NightstaRx Ltd – Key Competitors 18
NightstaRx Ltd – Key Employees 19
NightstaRx Ltd – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Aug 13, 2018: Nightstar Therapeutics reports second quarter 2018 financial results and business highlights 21
Aug 01, 2017: Nightstar Appoints Tuyen Ong as Chief Development Officer 23
Corporate Communications 24
Jul 13, 2017: Nightstar Appoints David Lubner to its Board of Directors 24
May 02, 2017: NightstaRx Appoints Ophthalmology Industry Veteran Scott Whitcup to Board of Directors 25
Apr 04, 2017: NightstaRx Appoints Healthcare Finance Leader Senthil Sundaram as Chief Financial Officer 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
NightstaRx Ltd, Pharmaceuticals & Healthcare, Key Facts 2
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NightstaRx Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NightstaRx Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
NightstaRx Ltd, Medical Devices Deals, 2012 to YTD 2018 9
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NightstaRx Raises USD45 Million in Series C Financing 11
NightstaRx Raises USD35 Million in Series B Financing Round 12
Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13
NightstaRx Raises US$19.8 Million In Venture Financing 14
NightstaRx Enters into Licensing Agreement with Oxford University 15
NightstaRx Expands Licensing Agreement with Isis Innovation 16
NightstaRx Enters into Licensing Agreement with Oxford University Innovation 17
NightstaRx Ltd, Key Competitors 18
NightstaRx Ltd, Key Employees 19

List of Figures
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NightstaRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
NightstaRx Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[NightstaRx Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ipsen Biopharmaceuticals Inc:企業の戦略的SWOT分析
    Ipsen Biopharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • MolMed SpA (MLM):製薬・医療:M&Aディール及び事業提携情報
    Summary MolMed SpA (Molmed) is a biotechnology company which offers research, development, manufacturing and clinical validation of novel anticancer therapies. Its pipeline antitumour products include Zalmoxis (TK), a cell based therapy enabling bone marrow transplants donors for the treatment of hi …
  • ThyssenKrupp AG:企業の戦略・SWOT・財務情報
    ThyssenKrupp AG - Strategy, SWOT and Corporate Finance Report Summary ThyssenKrupp AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Belfius Bank Sa
    Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report Summary Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • InteRNA Technologies BV:製薬・医療:M&Aディール及び事業提携情報
    Summary InteRNA Technologies BV (InteRNA) is a biotechnology company that develops RNA therapeutics for the treatment of cancer. The company develops technologies in biomedical research translating miRNA sequence fields. Its drug development programs offers developing miRNA-based therapeutics that c …
  • Taiwan Power Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Taiwan Power Company Ltd (Taiwan Power) is an integrated state-owned electric utility that offers electricity generation, transmission and distribution services. The utility generates electricity through various fuel resources including thermal, coal, gas, cogeneration and renewable sources. …
  • Proengin SA:企業の戦略・SWOT・財務分析
    Proengin SA - Strategy, SWOT and Corporate Finance Report Summary Proengin SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • First Abu Dhabi Bank (FAB):企業の財務・戦略的SWOT分析
    First Abu Dhabi Bank (FAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Olympus Corp (7733):医療機器:M&Aディール及び事業提携情報
    Summary Olympus Corporation (Olympus) provides precision machinery and instruments. It develops, manufactures and markets equipment and devices for medical, healthcare, imaging, information, and other industrial markets. It offers medical systems such as endotherapy devices, medical endoscopes and t …
  • CorEnergy Infrastructure Trust Inc (CORR):企業の財務・戦略的SWOT分析
    CorEnergy Infrastructure Trust Inc (CORR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Nativis Inc:医療機器:M&Aディール及び事業提携情報
    Summary Nativis Inc (Nativis) is a clinical stage bio-electronics company. The company provides portfolio of pipeline candidates which are under development for various therapeutic areas such as recurrent glioblastoma, brain metastisis, pain, rheumatoid arthritis, lung cancer and melanoma, among oth …
  • Cyclacel Pharmaceuticals Inc (CYCC):製薬・医療:M&Aディール及び事業提携情報
    Summary Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, selicicli …
  • Bosideng International Holdings Limited
    Bosideng International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Bosideng International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Brookdale Senior Living, Inc.:企業の戦略・SWOT・財務分析
    Brookdale Senior Living, Inc. - Strategy, SWOT and Corporate Finance Report Summary Brookdale Senior Living, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Cognition Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cognition Therapeutics Inc (CogRx) is a drug discovery and development company that discovers and develops small molecule therapeutics to improve the lives of individuals with Alzheimer’s disease and other neurocognitive disorders. The company uses its proprietary biology and chemistry platf …
  • Euler Hermes SA:企業の戦略・SWOT・財務情報
    Euler Hermes SA - Strategy, SWOT and Corporate Finance Report Summary Euler Hermes SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Omega Diagnostics Group Plc (ODX):企業の製品パイプライン分析
    Summary Omega Diagnostics Group Plc (Omega) is a biotechnology company that provides in-vitro diagnostic products. The company offers products in the areas of allergy, food intolerance, autoimmune disease and infectious disease, among others. It also provides food intolerance and autoimmune tests fo …
  • Genesis Energy, L.P.:企業の戦略・SWOT・財務分析
    Genesis Energy, L.P. - Strategy, SWOT and Corporate Finance Report Summary Genesis Energy, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Dermalogica Inc:企業の戦略・SWOT・財務情報
    Dermalogica Inc - Strategy, SWOT and Corporate Finance Report Summary Dermalogica Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Centrica Plc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Centrica Plc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Centrica Plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆